Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Efalizumab.
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Efalizumab.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Efalizumab.
Advertisement
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Efalizumab.
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Efalizumab.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Efalizumab.
Advertisement
Fingolimod
Efalizumab may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Efalizumab.
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Efalizumab.
Advertisement
Leflunomide
The risk or severity of adverse effects can be increased when Efalizumab is combined with Leflunomide.
Natalizumab
The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Efalizumab.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Efalizumab.
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Efalizumab.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Efalizumab.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Efalizumab.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Efalizumab.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Efalizumab.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Efalizumab.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Efalizumab.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Efalizumab.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.
Tofacitinib
Efalizumab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Efalizumab.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Efalizumab.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Efalizumab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Efalizumab.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Efalizumab.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Efalizumab.
